Lipoprotein(a)and Atherosclerotic Cardiovascular Diseases:Evidence from Chinese Population  

作　　者：Jianjun Li 

机构地区：[1]Cardiometabolic Center,Fuwai Hospital,Chinese Academy of Medical Sciences,Beijing 100037,China

出　　处：《Cardiology Discovery》2023年第1期40-47,共8页心血管病探索（英文）

基　　金：the Capital Health Development Fund(201614035);CAMS Major Collaborative Innovation 517 Project(2016-12M-1-011)awarded to Dr.Jianjun Li.

摘　　要：Cardiovascular disease(CVD)is the leading cause of mortality worldwide.Multiple factors are involved in CVD,and emerging data indicate that lipoprotein(a)(Lp(a))may be associated with atherosclerotic cardiovascular disease(ASCVD)independent of other traditional risk factors.Lp(a)has been identified as a novel therapeutic target.Previous studies on the influence of Lp(a)in CVD have mainly used in western populations.In this review,the association of plasma Lp(a)concentration with ASCVD was summarized,with regards to epidemiological,population-based observational,and pathological studies in Chinese populations.Lp(a)mutations and copy number variations in Chinese populations are also explored.Finally,the impact of plasma Lp(a)levels on patients with type 2 diabetes mellitus,cancer,and familial hypercholesterolemia are discussed.

关 键 词：LIPOPROTEIN (a) EPIDEMIOLOGY ATHEROSCLEROTIC CARDIOVASCULAR DISEASES Chinese POPULATION 

分 类 号：R543[医药卫生—心血管疾病]